Avishay Sarfatti
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Avishay Sarfatti has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Adam Briki
General Pediatrics, Ashford and St. Peters Hospital, Surrey, UK
1 shared publication - Akhila Kavirayani
Paediatric Rheumatology Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital Oxford UK
1 shared publication - Bogdana Sabina Zoica
PICU, King’s College Hospital, London, UK
1 shared publication - David Garbera
Alder Hey Children’s Hospital NHS Foundation Trust, Liverpool, UK
1 shared publication - Dominic F. Kelly
Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, United Kingdom
1 shared publication - Dusan Raffaj
PICU, Nottingham University Hospitals NHS Trust, Nottingham, UK
1 shared publication
Latest Publications
- 10 September 2026
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 185 (10) , 735
POCUS for the general pediatrician: a narrative review of practical applications, policy, and training
Point-of-care ultrasound (POCUS) is increasingly recognized as a valuable bedside imaging modality in pediatric medicine, enabling rapid real-time patient assessment and procedural guidance. While its use is well established in pediatric emergency and critical care settings, its role in general pediatric practice is expanding. This narrative review summarizes the practical applications of POCUS relevant to general pediatricians, focusing on lung imaging, focused functional cardiac assessment, ultrasound-guided vascular access, and the image governance required for safe implementation. A narrative review of contemporary pediatric literature and relevant consensus guidance was undertaken, focusing on evidence applicable to general pediatric practice, including diagnostic performance, procedural utility, education, and governance. Evidence supports the use of POCUS in general pediatrics as a means to improve diagnostic confidence and procedural outcomes. Lung ultrasound demonstrates high diagnostic accuracy for common pediatric respiratory conditions, including consolidation and pleural effusion, and may reduce reliance on chest radiography. Focused cardiac ultrasound provides actionable insights into fluid responsiveness and ventricular function at the bedside, facilitating timely decision-making and early identification of cardiogenic shock. Ultrasound-guided vascular access improves cannulation success rates and reduces complication risks, especially in children with difficult access. Despite these benefits, the adoption of POCUS in general pediatrics remains uneven across Europe, primarily due to variability in training standards, credentialing processes, and institutional support. Conclusion: POCUS has the potential to enhance bedside pediatric assessment by improving diagnostic confidence, procedural safety, and responsiveness to clinical change. Safe and equitable integration into general pediatric practice will require structured training, clear governance, routine image archiving, and a coordinated approach to competency and implementation. What is Known: • POCUS supports bedside assessment and procedural success in pediatric emergency and critical care. • Lung, focused cardiac and ultrasound-guided vascular access may also benefit general pediatric practice. What is New: • This review defines a pragmatic core POCUS scope for general pediatricians. • It links that scope to image governance and an author-proposed tiered competency framework for European implementation.
- 10 September 2026
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 185 (10) , 735
POCUS for the general pediatrician: a narrative review of practical applications, policy, and training
Point-of-care ultrasound (POCUS) is increasingly recognized as a valuable bedside imaging modality in pediatric medicine, enabling rapid real-time patient assessment and procedural guidance. While its use is well established in pediatric emergency and critical care settings, its role in general pediatric practice is expanding. This narrative review summarizes the practical applications of POCUS relevant to general pediatricians, focusing on lung imaging, focused functional cardiac assessment, ultrasound-guided vascular access, and the image governance required for safe implementation. A narrative review of contemporary pediatric literature and relevant consensus guidance was undertaken, focusing on evidence applicable to general pediatric practice, including diagnostic performance, procedural utility, education, and governance. Evidence supports the use of POCUS in general pediatrics as a means to improve diagnostic confidence and procedural outcomes. Lung ultrasound demonstrates high diagnostic accuracy for common pediatric respiratory conditions, including consolidation and pleural effusion, and may reduce reliance on chest radiography. Focused cardiac ultrasound provides actionable insights into fluid responsiveness and ventricular function at the bedside, facilitating timely decision-making and early identification of cardiogenic shock. Ultrasound-guided vascular access improves cannulation success rates and reduces complication risks, especially in children with difficult access. Despite these benefits, the adoption of POCUS in general pediatrics remains uneven across Europe, primarily due to variability in training standards, credentialing processes, and institutional support. Conclusion: POCUS has the potential to enhance bedside pediatric assessment by improving diagnostic confidence, procedural safety, and responsiveness to clinical change. Safe and equitable integration into general pediatric practice will require structured training, clear governance, routine image archiving, and a coordinated approach to competency and implementation. What is Known: • POCUS supports bedside assessment and procedural success in pediatric emergency and critical care. • Lung, focused cardiac and ultrasound-guided vascular access may also benefit general pediatric practice. What is New: • This review defines a pragmatic core POCUS scope for general pediatricians. • It links that scope to image governance and an author-proposed tiered competency framework for European implementation.
- Open Access
- 1 January 2025
- Published by Wiley in Pediatrics International
- Vol. 67 (1) , e70241
Vitamin D may influence disease course in PIMS ‐ TS / MIS ‐C: An observational cohort study
Background: Pediatric multisystem inflammatory syndrome temporally associated with SARS‐CoV‐2 (PIMS‐TS) remains an enigmatic disease process, with phenotypic similarities to Kawasaki disease, although many patients present with transient cardiac dysfunction. Biomarkers help validate diagnosis, but the correlation of biomarkers to disease severity or prognosis is poorly understood. Design: We retrospectively reviewed PIMS‐TS patients treated in Oxford between May 2020 and May 2022. Data on demographics, presenting features, biochemical markers, treatment, and outcomes were reviewed, and patients with/without the need for vasoactive medications were compared. Results: We identified 63 patients, median age 10.3 years (range 1.2–15.2 years). Where tested, 51/54 (94.4%) were SARS‐CoV‐2‐antibody positive. Admissions followed regional peaks in SARS‐CoV‐2 infection. Forty children (63.5%) required vasoactive medications. Amongst those requiring vasoactive medications, peak NT‐pro‐BNP (median 11,363 ng/L vs. 3741 ng/L, p = 0.004) and length of stay (median 8.4 vs. 6.4 days, p = 0.021) were greater. Vitamin D levels inversely correlated with peak CRP (spearman r = −0.34, p = 0.007) and duration of vasoactive medications (spearman r = −0.34, p = 0.030). Furthermore, low serum vitamin D correlated with lower SARS‐CoV‐2 anti‐nucleocapsid titers (spearman r = 0.43, p = 0.0014). Children receiving IV methylprednisolone, 54/63 (85.7%) (of whom, 16/54 received IVIg and methylprednisolone) had a more rapid fall in CRP than those given IVIg alone (7/63; 11.1%) or no immunomodulatory treatment (2/63; 3.2%). No patients had coronary artery aneurysm or persistent cardiac sequelae at discharge. Conclusions: Methylprednisolone suppressed CRP early and without evidence of coronary aneurysm in this cohort. We demonstrate a relationship between vitamin D, SARS‐CoV‐2 anti‐nucleocapsid antibody production, inflammatory biomarkers, and duration of vasoactive medication, requiring further validation.
- 1 January 2025
- Published by Wiley in Pediatrics International
- Vol. 67 (1) , e70241
Open AccessVitamin D may influence disease course in PIMS ‐ TS / MIS ‐C: An observational cohort study
Background: Pediatric multisystem inflammatory syndrome temporally associated with SARS‐CoV‐2 (PIMS‐TS) remains an enigmatic disease process, with phenotypic similarities to Kawasaki disease, although many patients present with transient cardiac dysfunction. Biomarkers help validate diagnosis, but the correlation of biomarkers to disease severity or prognosis is poorly understood. Design: We retrospectively reviewed PIMS‐TS patients treated in Oxford between May 2020 and May 2022. Data on demographics, presenting features, biochemical markers, treatment, and outcomes were reviewed, and patients with/without the need for vasoactive medications were compared. Results: We identified 63 patients, median age 10.3 years (range 1.2–15.2 years). Where tested, 51/54 (94.4%) were SARS‐CoV‐2‐antibody positive. Admissions followed regional peaks in SARS‐CoV‐2 infection. Forty children (63.5%) required vasoactive medications. Amongst those requiring vasoactive medications, peak NT‐pro‐BNP (median 11,363 ng/L vs. 3741 ng/L, p = 0.004) and length of stay (median 8.4 vs. 6.4 days, p = 0.021) were greater. Vitamin D levels inversely correlated with peak CRP (spearman r = −0.34, p = 0.007) and duration of vasoactive medications (spearman r = −0.34, p = 0.030). Furthermore, low serum vitamin D correlated with lower SARS‐CoV‐2 anti‐nucleocapsid titers (spearman r = 0.43, p = 0.0014). Children receiving IV methylprednisolone, 54/63 (85.7%) (of whom, 16/54 received IVIg and methylprednisolone) had a more rapid fall in CRP than those given IVIg alone (7/63; 11.1%) or no immunomodulatory treatment (2/63; 3.2%). No patients had coronary artery aneurysm or persistent cardiac sequelae at discharge. Conclusions: Methylprednisolone suppressed CRP early and without evidence of coronary aneurysm in this cohort. We demonstrate a relationship between vitamin D, SARS‐CoV‐2 anti‐nucleocapsid antibody production, inflammatory biomarkers, and duration of vasoactive medication, requiring further validation.